Presentations and Interviews

 PresentationMediaDate
Interview with CEO Martin Jönsson and CSO Johan Sandin at Redeye about the ACD856 poster on an anti-inflammatory effect to be presented at CTAD, October 1, 2024 (Swedish) October 1, 2024
AlzeCures CEO, Martin Jönsson at Finwire (Swedish ) August 27, 2024
Watch the latest interview at Redeye with our CEO, Martin Jönsson (Swedish) August 20, 2024
Alzecure’s pain project TrkA-NAM presented at the pain conference IASP, Augusti 5-9 2024 – Pharmalogical Effects of ACD137, a Potent and Selective Negative Allosteric Modulator of TrkA August 7, 2024
CEO Martin Jönsson presents at Redeye Investor forum (Swedish) May 16, 2024
Interview at Redeye with CEO, Martin Jönsson (Swedish) May 6, 2024
SITDOWN at Finwire - AlzeCures CEO, Martin Jönsson about the rights issue (Swedish) May 2, 2024
Interview at Finwire with Johan Sandin, CSO (Swedish) May 2, 2024
Rights issue presentation with CEO Martin Jönsson (Swedish) May 2, 2024
AlzeCure's CEO Martin Jönsson at Redeye (Swedish) April 11, 2024
CEO Martin Jönsson presenting at Finwire (Swedish) April 10, 2024
AlzeCure's CEO Martin Jönsson at Redeye's event on Alzheimer's (Swedish) March 21, 2024
AlzeCure presents new preclinical data with NeuroRestore ACD856 at leading Alzheimer’s conference, AD/PD 2024 March 7, 2024
Expert Event - Advances in the treatment of Alzheimer’s disease – Small molecule Gamma-Secretase Modulators (GSMs) as promising disease-modifying treatments together February 19, 2024
Alzheimer’s disease and the amyloid hypothesis – Professor Henrik Zetterberg, MD, PhD, Gothenburg University & University College London, AlzeCure Pharma expert event February 19, 2024
Alzstatin: a small molecule disease modifying and preventive therapy against Alzheimer’s – Johan Sandin, PhD, CSO, AlzeCure; AlzeCure Pharma expert event with Johan Sandin, PhD, CSO, AlzeCure February 19, 2024
Welcome address, agenda & company overview, – Martin Jönsson, CEO, AlzeCure; AlzeCure Pharma expert event - Alzheimer’s around highly current gamma-secretase modulators February 19, 2024
AlzeCure at Nordic American Healthcare Conference, December 6-7, 2023 December 6, 2023
AlzeCure at Redeye Life Science Day 2023 on November 23, 2023 November 23, 2023
NeuroRestore ACD856, a Trk-PAM in clinical development for Alzheimer’s disease shows neuroprotective and neurorestorative effects_CTAD 2023 October 25, 2023
Clinical results from phase II study with ACD440 in patients with peripheral neuropathic pain. Scientific presentation at the Svenskt Smärtforum conference Oct 12- 13, 2023. October 12, 2023
AlzeCure at Redeye Neurology Theme Event CEO Martin Jönsson presented and answered questions about the latest developments and the company’s plans going forward. October 11, 2023
Article from Life Science Sweden – DUAL ACTION AGAINST ALZHEIMER’S IN ALZSTATIN October 2, 2023
AlzeCure ACD440 TRPV1 antagonist Ph 2 data, EFIC 2023 September 20, 2023
AlzeCure Pharma present at Finwire September 5, 2023
AlzeCure Pharma present at Finwire – CMO Märta Segerdahl September 5, 2023
AlzeCure Pharma present at Finwire – CSO Johan Sandin September 5, 2023
AlzeCure Pharma’s CEO Martin Jönsson – Infocus interview at Redeye Growth Day on June 1th , 2023 June 1, 2023
AlzeCure presents at Redeye Growth Day on June 1st , 2023 June 1, 2023
Alzstatin – A preventive treatment against Alzheimer’s – Background & Evolution with Johan Sandin May 17, 2023
Presentation of the development of AlzeCure’s Alzheimer project Alzstatin and NeuroRestore May 17, 2023
Alzheimer’s disease; Challenges & Opportunities with Professor Bengt Winblad Karolinska Institutet May 17, 2023
NeuroRestore: Background & data supporting disease modifying effects with Pontus Forsell May 17, 2023
AlzeCure Pharma – Capital Market Day May 17th, 2023 May 17, 2023
Interview at Finwire with CEO Martin Jönsson May 9, 2023
CEO Martin Jönsson at Redeye (Swedish) April 12, 2023
Effects on neuroprotection and neuro plasticity by the clinical compound ACD856, a novel positive modulator of Trk-receptors from the NeuroRestore® platform; AD/PD 2023, March 28 – April 1, 2023 March 28, 2023
In vitro and in vivo profile of AC-0027875 (Alzstatin ACD680), a novel gamma-secretase modulator for the prevention and treatment of Alzheimer’s disease; AD/PD 2023, March 28 – April 1, 2023 March 28, 2023
Sitdown at Finwire with CEO Martin Jönsson March 1, 2023
Watch the interview at Redeye with CEO Martin Jönsson and Märta Segerdahl MD, PhD. Last patient included in AlzeCure’s Phase II clinical trial in peripheral neuropathic pain with the non-opioid ACD440. (Swedish) January 31, 2023
CEO Martin Jönsson’s interview with Redeye, the outcome of the issue and milestones in 2023, 9 January (Swedish) January 9, 2023
Erik Penser – Interview with CSO Johan Sandin about AlzeCure’s projects. December 13, 2022
Interview at Finwire news with CEO Martin Jönsson (The presentation will be held in Swedish). December 12, 2022
Erik Penser – Interview with Martin Jönsson about the ongoing Rights Issue. December 6, 2022
Rights Issue presentation with CEO Martin Jönsson at Erik Penser Bank. December 6, 2022
CEO Martin Jönsson presents AlzeCure at BioStock. December 5, 2022
AlzeCure’s CEO Martin Jönsson presents at BioStock in connection with a new share issue, December 5, 2022. December 5, 2022
Quantitative EEG results from a multiple ascending dose study. Scientific presentation at the CTAD conference nov 29- 2dec, 2022. November 30, 2022
AC-0027875, a novel gamma-secretase modulator. Scientific presentation at the CTAD conference nov 29- 2dec, 2022. November 30, 2022
Preclinical characterization of ACD856. Scientific presentation at the CTAD conference nov 29- 2dec, 2022. November 30, 2022
CEO Martin Jönsson interviewed at Redeye Life Sciences Day on the company’s positive development & plans, as well as about the proposed rights issue in December and the positive progress in the Alzheimer’s market, and what this means for AlzeCure. November 24, 2022
Martin Jönsson presented at Life Science Investor Conference the company’s successes and ongoing projects, as well as the company’s new share issue. November 23, 2022
CEO Martin Jönsson presents AlzeCure’s progress and ongoing projects, as well as the company’s proposed share issue. (English) November 17, 2022
Aktiespararna’s event with AlzeCure on November 16, 2022 – Martin Jönsson, AlzeCure’s CEO, presented the company’s progress and ongoing projects, as well as the company’s planned share issue. The presentation was held in Swedish. November 16, 2022
CEO Martin Jönsson presented an update on our Pain management projects at Redeye Theme: Neurology on October 12. October 12, 2022
CEO Martin Jönsson presented the company’s latest developments at Redeye Theme: Neurology on October 12, 2022. October 12, 2022
The Trk-PAM ACD856 improves mitochondrial function and increases BDNF levels in primary cortical neurons; Scientific presentation at the ISMND Conference, Athens, October 10-12, 2022. October 11, 2022
Analgesic and Anti-inflammatory Effects of Small Molecule Negative Allosteric Modulators of TrkA; Scientific presentation at the IASP Conference, Toronto, September 19-23, 2022. September 22, 2022
Martin talks about the latest developments for AlzeCure including the phase 2 study with ACD 440 against neuropathic pain, the new positive clinical results with NeuroRestore ACD 856, our new patent and the new results with the pain project TrkA-NAM. (Swedish). September 12, 2022
Interview with CEO Martin Jönsson and CSO Johan Sandin at Redeye about the latest clinical progress (Swedish). September 1, 2022
Results From a Multiple Ascending Dose Study in Healthy Volunteers of ACD856, a Positive Modulator of Neurotrophin Trk-Receptors AAIC July – Aug 2022. July 31, 2022
Watch the interview with Aktiespararna at Finwire with AlzeCure’s CEO Martin Jönsson. (Swedish). July 1, 2022
AlzeCure – Interview at Redeye with CEO Martin Jönsson about the phase II study with ACD440. (Swedish). June 23, 2022
AlzeCure at Redeye Growth Day. June 2, 2022
CEO Martin Jönsson Presenting at Redeye Growth Day. May 23, 2022
The use of PathHunter cell lines to discover modulators of Trk-receptors. From HTS to phase 1; Scientific presentation at the ELRIG Conference, Gothenburg, May 10-12, 2022. May 10, 2022
AlzeCure – Alzheimer event at Redeye (Swedish). May 3, 2022
Identification of a positive modulator of neurotrophin recptors with memory-enhancing effects and improved mitochondrial function; Scientific presentation at the 2nd Swedish Meeting for Alzheimer Research. April 21, 2022
Preliminary Results From a Single Ascending Dose Study in Healthy Volunteers of ACD856, a Positive Modulator of Neurotrophin Trk-Receptors; Scientific presentation at the 2nd Swedish Meeting for Alzheimer Research, Stockholm, April 21, 2022
Development of novel gamma-secretase modulators for the treatment of Alzheimer’s disease; Scientific presentation at the 2nd Swedish Meeting for Alzheimer Research, Stockholm. April 21, 2022
A positive modulator of neurotrophin receptors improves cognition and mitochondrial function; Scientific presentation at the AD/PD conference, Barcelona, March 15-20, 2022. March 17, 2022
NeuroRestore – Preliminary results from a Single Ascending Dose study in healthy volunteers of ACD856, a positive modulator of Neurotrophin Trk-receptors; Scientific presentation at the AD/PD conference, Barcelona, March 15-20, 2022 March 15, 2022
Watch the Analysisguide’s interview with AlzeCure’s CEO Martin Jönsson – about events in the company and the future (in Swedish). March 14, 2022
CEO Martin Jönsson is interview by BioStock on the company’s latest developments, including the ongoing rights issue. March 14, 2022
CSO Johan Sandin explains the science behind AlzeCure’s project portfolio and what distinguishes it from other pharma companies (Swedish). March 14, 2022
See CEO Martin Jönsson and CSO Johan Sandin, present upcoming events in the company and the ongoing issue (Swedish). March 11, 2022
Watch the interview with AlzeCure’s CEO Martin Jönsson – about events in the company and the ongoing issue (Swedish). March 9, 2022
AlzeCure – New presentation at Penser (Swedish). February 24, 2022
Latest newsflow (Swedish). February 3, 2022
CEO Martin Jönsson presents at Aktiespararna (Swedish). January 31, 2022
Alzstatin – Development of novel gamma-secretase modulators for the treatment of Alzheimer’s disease, Scientific presentation at 11th Pharmaceutical Profiling meeting, January 27, 2022. January 27, 2022
Alzstatin – Development of novel ?-secretase modulators for the treatment of Alzheimer’s disease. January 27, 2022
Alzstatin – Development of novel gamma-secretase modulators for the treatment of Alzheimer’s disease (Text only). January 27, 2022
AlzeCure Pharma – Kapitalmarknadsdag. January 18, 2022
AlzeCure medverkar på Erik Penser Banks temadag Life Science december 2, 2021 (Swedish) December 2, 2021
Follow us – Stay updated November 22, 2021
AlzeCure Pharma – Redeye Life Science Day November 11, 2021
AlzeCure update on the latest developments – Interview with CEO Martin Jönsson about the company, its projects developments in Alzheimer’s and pain, and future plans. October 22, 2021
Alzecure presents at Healthcare Innovation Summit October 7, 2021
Characterization of positive allosteric modulators of TrkB for the treatment of depression October 2, 2021
Alzecure Pharma – Naventus Life Science Summit September 29, 2021
Aktiespararna interview CEO Martin Jönsson – latest quarterly report and future prospects. (Swedish) September 20, 2021
AlzeCure Pharma – Aktiedagen Stockholm. (Swedish) September 7, 2021
Development plan for NeuroRestore ACD856 by Dr Johan Sandin, PhD Chief Scientific Officer September 1, 2021
NeuroRestore Background and evolution by Dr Pontus Forsell, PhD Head of Discovery & Research September 1, 2021
Company Overview & Vision by Martin Jönsson CEO September 1, 2021
Alzheimer’s disease and the neurotrophins BDNF/NGF by Prof. Maria Eriksdotter M.D., PhD September 1, 2021
Strategy Update on Alzheimer’s Disease & NeuroRestore September 1, 2021
ACD856 – a novel positive allosteric modulator of Trk-receptors in clinical development for the treatment of Alzheimer’s disease; Scientific presentation at AAIC, July 26-30, 2021 July 29, 2021
About AlzeCure’s origin and development – An embryo that can be something big – with Bengt Winblad, professor, senior at Karolinska Institutet. (Swedish) June 11, 2021
Negative Allosteric Modulators of TrkA for the Treatment of Pain – Scientific presentation at the IASP conference on pain, June 2021 June 11, 2021
About suffering from Alzheimer’s disease, diagnostics, care today and future needs – with Bengt Winblad, professor, senior at Karolinska Institutet. (Swedish) June 11, 2021
About Alzstatin and drugs for Alzheimer’s disease – with Bengt Winblad, professor, senior at Karolinska Institutet. (Swedish) June 11, 2021
ACD440 – A Novel TRPV1 Antagonist for the Topical Treatment in Neuropathic Pain – Scientific presentation at the IASP conference on pain, June 2021 June 9, 2021
Alzecure: CEO Martin Jönsson present at Redeye Growth Day June 7, 2021
CEO presentation at the annual meeting (Swedish) May 20, 2021
CEO Martin Jönsson after the company’s annual meeting May 17, 2021
Update on Progress in the Painless Platform, May 11, 2021 May 11, 2021
Company overview and goals by CEO Martin Jönsson, May 11, 2021 May 11, 2021
Chronic Pain – a high unmet medical need by CMO Märta Segerdahl, May 11, 2021 May 11, 2021
ACD 440 – A novel VR1 antagonist for neuropathic pain by CSO Johan Sandin, May 11, 2021 May 11, 2021
TrkA- NAM – Project in osteoarthritis & other severe pain conditions by Head of Discovery & Research Pontus Forsell, May 11, 2021 May 11, 2021
Alzecure: Interview with CEO Martin Jönsson and CSO Johan Sandin (video) April 20, 2021
Alzecure: Interview with CEOMartin Jönsson (video). (Swedish) March 1, 2021
Interview with Martin Jönsson CEO in Aktiespararna’s analysis guide February 8, 2021
CEO Martin Jönsson presentation, Aktiedagen Lund January 27, 2021
Interview with Johan Sandin (CSO) in Aktiespararna’s analysis guide January 22, 2021
Improving Quality of Life for People with Neurodegenerative Diseases – Stockholm Researchers and Health Tech Companies January 14, 2021
Alzecure: CEO Martin Jönsson presents at Redeye Life Science Day 2020 December 1, 2020
Scientific presentation on the NeuroRestore® candidate ACD856 presented at the CTAD conference November 4, 2020
Scientific presentation on Alzstatin presented at the CTAD conference November 4, 2020
Scientific and market update with professor Henrik Zetterberg on Alzheimer’s disease, bio-markers, potential future treatments, including Alzstatin and AlzeCure September 30, 2020
AlzeCure presentation with CEO Martin Jönsson at Aktiespararna (Swedish) September 8, 2020
AlzeCure Science & Market update about Alzheimer’s diseas and NeuroRestore (Swedish) September 1, 2020
Scientific presentation about ACD856, a positive modulator of neurotrophin signaling reverses scopolamine- or age-induced cognitive deficits April 2, 2020
Get to know AlzeCure’s CEO Martin Jönsson – Redeye interview (Swedish) March 19, 2020
AlzeCure presentation with CEO Martin Jönsson at Aktiespararna (Swedish) March 16, 2020
Gamma-secretase modulation results in multiple anti-amyloidogenic effects in vivo; Scientific presentation at the AAT-AD/PD conference, Italy, March 15-18, 2018 March 15, 2018
About the Alzstatin® project Disease modifying treatment of Alzheimer’s disease February 27, 2018
Welcome to AlzeCure … Introduction film about the company (Swedish) – 1 minute February 27, 2018
About the project NeuroRestore®, symptomatic treatment of cognitive disorders such as in Alzheimer’s disease February 27, 2018
About Alzheimers disease February 27, 2018